DDInter1140 DDInter927
Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Mefloquine {u} (Compound) resembles {v} (Compound) Flecainide
Mefloquine {u} (Compound) binds {v} (Gene) ACHE
Mefloquine {u} (Compound) upregulates {v} (Gene) DDIT4
Mefloquine {u} (Compound) downregulates {v} (Gene) RRP12
Mefloquine {u} (Compound) causes {v} (Side Effect) Leukocytosis
Mefloquine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metoclopramide
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Valproic acid
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Ibutilide
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Pimozide
Mefloquine (Compound) resembles Flecainide (Compound)
Mefloquine (Compound) binds ACHE (Gene)
Mefloquine (Compound) upregulates DDIT4 (Gene)
Mefloquine (Compound) downregulates RRP12 (Gene)
Mefloquine (Compound) causes Leukocytosis (Side Effect)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Valproic acid
Mefloquine may lead to a major life threatening interaction when taken with Ibutilide
Mefloquine may lead to a major life threatening interaction when taken with Pimozide